Prof. Stephen Faraone, Ph.D. to present on October 25 in Seattle, Washington
COLUMBIA, Md., Oct. 09, 2018 (GLOBE NEWSWIRE) — VAYA™ Pharma, Inc. (VAYA™), a division of Frutarom, Inc., and leader in developing specialty nutrition and medical food products, announced today the presentation of new data from its Vayarin® Plus clinical study of adults with attention-deficit hyperactivity disorder (ADHD). Stephen Faraone, Ph.D. distinguished professor of psychiatry and of neuroscience and physiology at SUNY Upstate Medical University, will present the clinical study findings at the American Academy of Child and Adolescent Psychiatry (AACAP) annual meeting on October 25 at 1:30 p.m. in Seattle, Washington. During the presentation, Prof. Faraone will discuss the advanced Sequential Parallel Comparison Design (SPCD) study design that was used in the trial to minimize placebo effect. Prof. Faraone is a member of the VAYA advisory board and a clinical advisor of the clinical study.
“In our per protocol analysis, we see clinically meaningful and statistically significant improvements in the study across multiple rating scales that measure functional impairments in the life of adults with ADHD,” said Dr. Gali Artzi, director of medical affairs, VAYA™. “In terms of safety, Vayarin® Plus was well-tolerated with virtually no side effects. We are pleased to see the benefit that patients and their families can have from Vayarin® Plus. ”
VAYA™ will exhibit at the AACAP meeting (booth number 211).
Vayarin® Plus Clinical Study
The data comes from a multi-centered, double-blind, placebo-controlled clinical trial of 189 adults with ADHD. The clinical trial studied the effect of Vayarin® Plus, phosphatidylserine attached to omega-3 enriched with eicosapentaenoic acid (EPA), on the management of ADHD in adults. The study results showed the potential of Vayarin® Plus to effectively and safely improve ADHD behaviors in adults.
About Vayarin® Plus
Vayarin® Plus, a new extra-strength product in the Vayarin® product family, is indicated for the clinical dietary management of ADHD in adults and adolescents over the age of 14 who weigh 97 pounds or above (44kgs). Literature supports strong correlation between lipid imbalances and ADHD. Vayarin® Plus compensates for and manages these imbalances and was clinically shown to reduce ADHD behaviors safely and effectively, providing full-day coverage.
For more information about VAYA™ Pharma and about Vayarin® Plus, please visit www.vayadirect.com.
VAYA™ Pharma, a division of Frutarom, Inc., is the innovator of lipid-based medical foods that are used to manage distinct nutritional deficiencies associated with certain diseases and health conditions, including Attention Deficit Hyperactivity Disorder (ADHD) and Early Memory Impairment (EMI). Committed to safety and efficacy, VAYA™ Pharma’s innovations – Vayarin®, Vayarin® Plus and Vayacog® – are backed by years of clinical research. VAYATM Pharma is headquartered in Columbia, Maryland.
For more information:
View source version on globalnewswire.com: https://goo.gl/GvVnC5